This review published in Nephrology and Hypertension examines the role of urinary citrate in autosomal dominant polycystic kidney disease (ADPKD), with a focus on its potential as both a prognostic biomarker and a therapeutic target.

Evidence from experimental and clinical studies suggests that hypocitraturia in early ADPKD may contribute to calcium microcrystal deposition, promoting cyst formation and accelerated kidney function decline.

Animal models show that citrate supplementation may help preserve glomerular filtration rate and slow cyst growth. The authors propose that urinary citrate may aid in risk stratification and potentially serve as an adjunctive therapy, although further clinical research is needed. 

Read Original Article Here -->